edoc

The Survey on Cellular and Engineered Tissue Therapies in Europe in 2013

Martin, Ivan and Ireland, Hilary and Baldomero, Helen and Dominici, Massimo and Saris, Daniël B. and Passweg, Jakob. (2016) The Survey on Cellular and Engineered Tissue Therapies in Europe in 2013. Tissue Engineering, 22 (1-2). pp. 5-16.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/53052/

Downloads: Statistics Overview

Abstract

Following the coordinated efforts of five established scientific organizations, this report, the sixth of its kind, describes activity in Europe for the year 2013 in the area of cellular and engineered tissue therapies, excluding hematopoietic stem cell (HSC) treatments for the reconstitution of hematopoiesis. Three hundred eighteen teams from 31 countries responded to the cellular and engineered tissue therapy survey; 145 teams from 25 countries reported treating 2187 patients, while a further 173 teams reported no activity. Indications were musculoskeletal/rheumatological disorders (45%; 89% autologous), cardiovascular disorders (20%; 99% autologous), hematology/oncology, predominantly prevention or treatment of graft versus host disease (GvHD) and HSC graft enhancement, (19%; <1% autologous), neurological disorders (3%; 100% autologous), gastrointestinal disorders (2%; 32% autologous), and other indications (11%; 67% autologous). The majority of autologous cells (88%) were used to treat musculoskeletal/rheumatological (57%) and cardiovascular (27%) disorders, whereas allogeneic cells were used mainly for hematology/oncology (64%). The reported cell types were mesenchymal stem/stromal cells (MSC) (49%), HSC (28%), chondrocytes (11%), dendritic cells (2%), keratinocytes (1%), and others (9%). In 46% of the grafts, cells were delivered following ex vivo expansion, sorted in 17% of the reported cases and transduced in only 3%. Thirty three percent of treatments were delivered intravenously or intra-arterially, and of the remaining 67%, 37% used a membrane/scaffold, 28% a suspension, and 2% a gel. The data are compared to those previously collected to identify trends in a still unpredictably evolving field.
Faculties and Departments:03 Faculty of Medicine > Bereich Operative Fächer (Klinik) > Querschnittsbereich Forschung > Tissue Engineering (Martin)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Operative Fächer (Klinik) > Querschnittsbereich Forschung > Tissue Engineering (Martin)
03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Tissue Engineering (Martin)
UniBasel Contributors:Martin, Ivan
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Mary Ann Liebert
ISSN:1937-3376
e-ISSN:1937-335X
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:09 Oct 2017 06:49
Deposited On:09 Oct 2017 06:49

Repository Staff Only: item control page